Accelerated assessment fast-tracks Lenvima to benefit patients with thyroid cancer

View source ↗

Summary

The European Medicines Agency granted accelerated assessment for Lenvima, speeding its evaluation to benefit patients with thyroid cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Cancer

Drugs mentioned

• LENVIMA (lenvatinib)